-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Benzinga·07/30/2026 19:25:31
Listen to the news
Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $28 to $22.